Inotiv, Inc. ((NOTV)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inotiv’s latest earnings call painted a mixed picture for investors. The DSA business is clearly gaining momentum with double‑digit growth, stronger margins and a rising backlog, signaling healthy demand. Yet this progress is overshadowed by widening losses, shrinking cash, high debt and pressure in the RMS segment, leaving the near‑term risk profile elevated.
Moderate Revenue Growth Driven by DSA Strength
Total revenue in Q1 fiscal 2026 inched up to $120.9 million from $119.9 million a year earlier, a modest 0.8% gain. The small headline increase masks a sharp split, with DSA growth offsetting weakness in research models and services, underscoring how reliant Inotiv has become on its higher‑value DSA franchise.
DSA Segment Delivers Double‑Digit Expansion
DSA revenue jumped to $48.0 million from $42.8 million, up roughly 12% year over year. Within that, discovery and translational sciences surged 26% while safety assessment rose 7%, confirming that clients continue to lean on Inotiv’s higher‑margin scientific services even in a choppy macro backdrop.
Healthy DSA Awards, Backlog and Book‑to‑Bill
New awards in DSA reached $53.6 million, a 27% increase versus the prior‑year quarter, with discovery awards up 44% and safety assessment awards up 22%. Backlog climbed to $145.4 million and the DSA book‑to‑bill ratio of 1.16 for the quarter, and 1.08 on a trailing 12‑month basis, signals sustained demand and revenue visibility.
DSA Margins and Operating Income Improve
Management highlighted the strongest first‑quarter DSA margins in three years, reflecting both mix and operational leverage. Non‑GAAP DSA operating income rose to $8.2 million, or 6.8% of total revenue, up from $7.1 million and 5.9% a year ago, suggesting the segment can scale profitably as volumes build.
RMS Services Grow Amid Site Optimization Efforts
RMS services revenue increased 13% year over year, helped by higher non‑human primate colony management activity. In parallel, the company exited two leased facilities as part of a broader site optimization plan slated to finish by the third quarter of fiscal 2026, with logistics and fleet initiatives aimed at lifting margins over time.
Refinancing Efforts Highlight Balance‑Sheet Strain
Inotiv has hired Perella Weinberg Partners to explore refinancing options, a clear acknowledgment of its heavy leverage and high interest burden. The company also secured a lender waiver for first‑quarter covenant noncompliance, indicating lenders’ willingness to cooperate but also underscoring the urgency of repairing the capital structure.
Consolidated Losses and Weak Adjusted EBITDA
Despite operational progress in DSA, the company posted a consolidated net loss of $28.4 million versus a $27.6 million loss a year ago. Adjusted EBITDA slid to $1.8 million, or 1.5% of revenue, from $2.6 million, highlighting how rising interest costs and RMS softness are diluting the benefits of DSA growth at the consolidated level.
RMS Hit by Sharp Drop in NHP Volumes
RMS revenue fell to $72.9 million, down 5.4% year over year, primarily due to an estimated 25% decline in non‑human primate volumes. RMS non‑GAAP operating income dropped to $7.2 million, or 5.9% of revenue, from $9.4 million and 7.9% a year earlier, compressing margins and reducing the segment’s contribution to group profitability.
Cash Erosion and Elevated Leverage Levels
Cash and cash equivalents declined to $12.7 million at December 31 from $21.7 million at September 30, while total debt edged up to $405.8 million. The company tapped $6 million of its $15 million revolver and required a covenant waiver, leaving investors focused on liquidity and refinancing execution as key near‑term risk factors.
Operating Cash Use and Ongoing Capital Spending
Operations consumed $5.4 million of cash in the quarter versus $4.5 million a year earlier, reflecting losses and working‑capital needs. Capital expenditures were $5.2 million, about 4.3% of revenue, as management invests in site transitions but expects to keep full‑year CapEx below 4% to preserve cash once the optimization program matures.
High Interest Costs Continue to Weigh on Results
Interest expense remained heavy at $13.5 million for the quarter, only slightly below last year’s $13.8 million. This sizable financing burden is a major driver of pre‑tax losses and keeps pressure on adjusted EBITDA and net income, reinforcing why refinancing is central to the turnaround thesis.
Operational Disruptions Add Near‑Term Cost Noise
Management cited normal seasonality, weather‑related shipping disruptions in late January, tariff impacts and dual‑site running costs tied to the optimization program as margin headwinds. These factors contributed to quarter‑to‑quarter variability and diluted near‑term benefits from cost‑saving measures that are expected to show more fully after site consolidation.
Directional Outlook Without Formal 2026 Guidance
The company refrained from issuing formal fiscal 2026 guidance, pointing to uncertainty around demand and tariffs, but highlighted strong DSA awards, backlog and a book‑to‑bill above one as key positives. Management expects full‑year non‑human primate revenue to be roughly flat, CapEx under 4% of revenue and is prioritizing refinancing and cost optimization to stabilize liquidity and unlock the value of its growing DSA franchise.
In summary, Inotiv’s call showcased a DSA engine that is gaining traction, with robust bookings, a growing backlog and better margins suggesting a solid core business. However, RMS volume pressure, cash burn, high interest expense and leverage add significant execution risk, making the investment case hinge on successful refinancing and continued DSA outperformance over the coming quarters.